A Leading Comprehensive Genomic Profiling Approach
Our tests analyse all known cancer-relevant genes and detect the four main classes of genomic alterations in a single test.1,7–11 We leverage next-generation sequencing (NGS) technology to examine regions of the tumour genome that other tests miss.1,5,7–16 In the same test we also report microsatellite instability (MSI)* and tumour mutational burden (TMB)* alongside a comprehensive set of genes:7–16
Four main classes of genomic alterations
Tumour mutational burden
Insightful Results and Reporting
A clear, in-depth report supports clinical decision-making by providing insights on the patient’s genomic profile as well as associated targeted therapies, immunotherapies and relevant clinical trials.23
and Continuously Updated
The validation of our comprehensive genomic profiling services is published in top-tier peer-reviewed journals, and the services are supported by a large and growing body of clinical evidence.1,10,11,24,25
Our continuously growing genomic database currently includes over 200,000 genomic profiles in over 150 common and rare tumour subtypes, helping us to ensure our reporting of clinically-relevant genomic alterations is always up-to-date.26
MSI: microsatellite instability; NGS: next-generation sequencing; TMB: tumour mutational burden.
*TMB reported in FoundationOne®CDx and FoundationOne®Heme. MSI reported in FoundationOne CDx, FoundationOne®Liquid and FoundationOne Heme.
Results and Reporting
A clear, in-depth report supports clinical decision-making by providing insights on the patient’s genomic profile as well as associated targeted therapies, immunotherapies and relevant clinical trials.23 The report also highlights important disease-relevant genes with no reportable alterations identified and genomic alterations associated with potential resistance to therapy to help rule out potentially ineffective treatment.23
Please choose your country to explore more